Search Results - "Pileckytė, Regina"

Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation by Zucenka, Andrius, Vaitekenaite, Vilmante, Maneikis, Kazimieras, Davainis, Linas, Pileckyte, Regina, Trociukas, Igoris, Peceliunas, Valdas, Zvirblis, Tadas, Staras, Vytautas, Griskevicius, Laimonas

“…We retrospectively compared the outcomes of 20 patients receiving Venetoclax + low-dose Cytarabine + Actinomycin D (ACTIVE) with 29 patients receiving FLAG-Ida…”
Get full text

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA by Žučenka, Andrius, Vasilevska, Dominika, Daukėlaitė, Guoda, Trociukas, Igoris, Pečeliūnas, Valdas, Pileckyte, Regina, Griškevičius, Laimonas

Get full text

PB2005: AZACITIDINE IN COMBINATION WITH 14‐DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS‐2 IN CLINICAL PRACTICE SETTING by Žučenka, Andrius, Čepulytė, Rūta, Davainienė, Birutė, Vasilevska, Dominika, Pileckyte, Regina, Trociukas, Igoris, Pečeliūnas, Valdas, Griškevičius, Laimonas

Get full text

Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients by Zucenka, Andrius, Davainienė, Birutė, Vaitekėnaitė, Vilmantė, Čepulytė, Rūta, Davainis, Linas, Daukėlaitė, Guoda, Kevličius, Lukas, Pileckytė, Regina, Trociukas, Igoris, Griškevičius, Laimonas

“…Background Allogeneic stem cell transplantation (alloSCT) is the cornerstone therapy for myelodysplastic syndromes with increased blasts-2 (MDS-IB2). However,…”
Get full text

Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia by Pileckyte, Regina, Valceckiene, Vilma, Stoskus, Mindaugas, Matuzeviciene, Reda, Sejoniene, Jurgita, Zvirblis, Tadas, Griskevicius, Laimonas

“…: BTK and BCL2 inhibitors have changed the treatment paradigms of high-risk and elderly patients with chronic lymphocytic leukemia (CLL), but their long-term…”
Get full text

Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting by Zucenka, Andrius, Vaitekėnaitė, Vilmantė, Maneikis, Kazimieras, Pileckytė, Regina, Trociukas, Igoris, Pečeliūnas, Valdas, Griškevičius, Laimonas

“…Background Venetoclax based therapies have produced varying results in the relapsed or refractory acute myeloid leukemia (R/R AML) setting. Highest response…”
Get full text

Venetoclax-Based Therapies for Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 in Clinical Practice Setting by Žucenka, Andrius, Kevličius, Lukas, Davainis, Linas, Davainienė, Birutė, Maneikis, Kazimieras, Pileckytė, Regina, Vasilevska, Dominika, Trociukas, Igoris, Vaitekėnaitė, Vilmantė, Griškevičius, Laimonas

Get full text

AML-377 Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations by Daukėlaitė, Guoda, Vasilevska, Dominika, Vaitekėnaitė, Vilmantė, Trociukas, Igoris, Pileckytė, Regina, Griškevičius, Laimonas, Žučenka, Andrius

“…IDH1/2 inhibitors (IDHi) ivosidenib, olutasidenib and enasidenib are US Food and Drug Administration-approved salvage therapies for IDH-mutated (IDHm) R/R AML…”
Get full text

POSTER: AML-377 Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations by Daukėlaitė, Guoda, Vasilevska, Dominika, Vaitekėnaitė, Vilmantė, Trociukas, Igoris, Pileckytė, Regina, Griškevičius, Laimonas, Žučenka, Andrius

Get full text

POSTER: AML-519 Sequential Allogeneic Stem Cell Transplantation (alloSCT) After Venetoclax (Ven)-Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Myelodysplastic Syndrome With Excess Blasts 2 (MDS-EB2) by Vasilevska, Dominika, Daukėlaitė, Guoda, Trociukas, Igoris, Pileckytė, Regina, Griškevičius, Laimonas, Žučenka, Andrius

Get full text

AML-519 Sequential Allogeneic Stem Cell Transplantation (alloSCT) After Venetoclax (Ven)-Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Myelodysplastic Syndrome With Excess Blasts 2 (MDS-EB2) by Vasilevska, Dominika, Daukėlaitė, Guoda, Trociukas, Igoris, Pileckytė, Regina, Griškevičius, Laimonas, Žučenka, Andrius

“…It remains unclear whether complete remission (CR) is necessary to proceed to alloSCT for R/R AML or MDS-EB2, especially in the era of targeted therapy. To…”
Get full text

Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities by Stoskus, Mindaugas, Gineikiene, Egle, Valceckiene, Vilma, Valatkaite, Beatrice, Pileckyte, Regina, Griskevicius, Laimonas

“…Insulin-like growth factor 2 mRNA-binding proteins IGF2BP1, IGF2BP2, and IGF2BP3 have been shown to have diagnostic and prognostic utility in a number of…”
Get full text

Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS) by Kevličius, Lukas, Smalinskaitė, Tautvilė, Trociukas, Igoris, Pileckytė, Regina, Čekauskienė, Rita, Davainis, Linas, Daukėlaitė, Guoda, Vaitekėnaitė, Vilmantė, Strumskytė, Justė, Jaraminė, Vaida, Slobinas, Artūras, Jucaitienė, Renata, Šlepikienė, Inga, Bukauskas, Adomas, Stoškus, Mindaugas, Batiuškaitė, Raminta, Norvilas, Rimvydas, Velčeckienė, Vilma, Gineikienė Valentinė, Eglė, Dirsė, Vaidas, Griškevičius, Laimonas, Žučenka, Andrius

Get full text

AML-672 Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS) by Kevlčius, Lukas, Smalinskaitė, Tautvilė, Trociukas, Igoris, Pileckytė, Regina, Čekauskienė, Rita, Davainis, Linas, Daukėlaitė, Guoda, Vaitekėnaitė, Vilmantė, Strumskytė, Justė, Jaraminė, Vaida, Slobinas, Artūras, Jucaitienė, Renata, Šlepikienė, Inga, Bukauskas, Adomas, Stoškus, Mindaugas, Batiuškaitė, Raminta, Norvilas, Rimvydas, Velčeckienė, Vilma, Valentinė, Eglė Gineikienė, Dirsė, Vaidas, Griškevičius, Laimonas, Žučenka, Andrius

“…The optimal induction strategy and timing for alloSCT in cases of R/R AML or HR-MDS have yet to be clearly determined. To evaluate the efficacy and toxicity of…”
Get full text

POSTER: AML-299 Azacitidine in Combination With Venetoclax for Myelodysplastic Syndrome (MDS) With Increased Blasts-2 in Clinical Practice Setting by Davainiene, Birute, Cepulyte, Ruta, Trociukas, Igoris, Pileckyte, Regina, Griskevicius, Laimonas, Zucenka, Andrius

Get full text

AML-299 Azacitidine in Combination With Venetoclax for Myelodysplastic Syndrome (MDS) With Increased Blasts-2 in Clinical Practice Setting by Davainiene, Birute, Cepulyte, Ruta, Trociukas, Igoris, Pileckyte, Regina, Griskevicius, Laimonas, Zucenka, Andrius

“…Azacitidine + venetoclax (AZA+VEN) is currently an investigational therapy for high-risk MDS. We have reviewed our real-life experience with MDS-IB2 patients…”
Get full text

Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies by Zucenka, Andrius, Pileckyte, Regina, Trociukas, Igoris, Peceliunas, Valdas, Vaitekenaite, Vilmante, Maneikis, Kazimieras, Davainis, Linas, Zvirblis, Tadas, Stoskus, Mindaugas, Gineikiene, Egle, Norvilas, Rimvydas, Dirse, Vaidas, Surauciute, Agne, Zucenkiene, Emile, Griskevicius, Laimonas

“…Objectives and methods We conducted a retrospective analysis to evaluate the outcomes of 28 heavily pretreated (median 3 (2‐6) treatment lines, sixteen (57%)…”
Get full text

Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia by Pileckyte, Regina, Jurgutis, Mindaugas, Valceckiene, Vilma, Stoskus, Mindaugas, Gineikiene, Egle, Sejoniene, Jurgita, Degulys, Andrius, Zvirblis, Tadas, Griskevicius, Laimonas

“…This study evaluated the efficacy and safety of dose-dense high-dose methylprednisolone (HDMP) plus rituximab (Rtx) in patients with high-risk CLL. Twenty-nine…”
Get full text